Proparacaine (proparacaine HCl)

It isessential that the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:

Usual dosage in adults and pediatric patients: for removal of foreign bodies and sutures and for tonometry, apply 1 to 2 drops (in single instillations) in each eye before operating.

Short corneal and conjunctival procedures in adults and pediatric patients: apply 1 drop in each eye every 5 to 10 minutes for 5 to 7 doses.

FOR TOPICAL OPHTHALMIC USE ONLY. NOT FOR INJECTION.

Apply topically to the eye in the form of a 0.5% solution.

Administer under the direct supervision of a healthcare provider; not intended for patient self-administration.

Store bottles under refrigeration at 2degreesC to 8degreesC in unit carton to protect contents from light.

After opening, proparacaine can be used until the expiration date on the bottle.

The ophthalmic solution should be clear to straw-color. If the solution becomes darker, discard the solution.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

Known hypersensitivity to any of the ingredients of this preparation.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

Occasional temporary stinging, burning and conjunctival redness may occur with the use of proparacaine. Corneal edema has been reportedfollowing the use of proparacaine. A rare, severe, immediate-type, apparently hyperallergic corneal reaction characterized by acute, intense and diffuse epithelial keratitis, a gray, ground glass appearance, sloughing of large areas of necrotic epithelium, corneal filaments and, sometimes, iritis with descemetitis has been reported.

Allergic contact dermatitis with drying and fissuring of the fingertips has also been reported.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

Safety and effectiveness of proparacaine hydrochloride ophthalmic solution in pediatric patients have been established. Use of proparacaine hydrochloride is supported by evidence from adequate and well-controlled studies in adults and children older than 12 years of age, and safety information in neonates and other pediatric patients.

Animal reproduction studies have not been conducted with proparacaine hydrochloride ophthalmic solution. It is also not known whether the drug can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Proparacaine should be administered to a pregnant woman only if clearly needed.

It is not known whether proparacaine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when proparacaine is administered to a nursing woman.

No overall clinical differences in safety or effectiveness have been observed between the elderly and other adult patients.